NLE Perioperative & Pain Nursing — Pain ManagementSummary

Pain is defined as 'whatever the patient says it is, existing whenever the patient says it does.' This foundational principle, established by McCaffery, emphasizes that pain is a subjective experience and the patient's self-report is the most reliable and valid indicator of pain presence and intensity. Unlike objective vital signs such as blood pressure or heart rate, pain cannot be measured directly by the nurse—it must be believed and acted upon based on the patient's report. This principle underlies all assessment and management approaches and reflects respect for patient autonomy, a core value in RA 9173 nursing practice.

Nociceptive pain (pain from actual tissue injury) involves four sequential physiologic processes: (1) **Transduction**—a noxious stimulus (mechanical, thermal, or chemical injury) activates specialized nerve endings called nociceptors, converting the stimulus into an electrical nerve impulse. (2) **Transmission**—the impulse travels along peripheral nerves (A-delta and C fibers), through the dorsal horn of the spinal cord, and up the spinothalamic tract to the brain (brainstem and thalamus). (3) **Perception**—the brain becomes conscious of the pain signal in the cortex and limbic system, creating the conscious experience. (4) **Modulation**—descending inhibitory pathways from the brain release endogenous opioids (endorphins) and other neurotransmitters that dampen or amplify the pain signal at the spinal cord level. Understanding these processes explains why analgesics work at different levels and why multimodal approaches are effective.

Developed by Melzack and Wall, gate control theory proposes that non-painful sensory stimuli can 'close the gate' in the dorsal horn of the spinal cord, reducing the transmission of pain signals to the brain. Large-diameter A-beta fibers (carrying touch, pressure, vibration) close the gate, while pain fibers (A-delta and C) attempt to open it. This mechanism explains why patients instinctively rub a bumped knee, why massage feels soothing, why distraction helps, and why application of heat or cold relieves pain. The brain itself can also modulate gates through attention, emotion, and prior experience. Gate control is the physiologic rationale for non-pharmacologic pain management and explains why combining drug and non-drug strategies is more effective than either alone.

**Acute pain** begins suddenly (recent onset), serves a protective/warning function signaling tissue injury, and resolves as tissue heals (typically within 3–6 months). Acute pain triggers sympathetic nervous system responses: tachycardia, hypertension, diaphoresis, pupil dilation, and anxiety. These objective signs are present and expected. Examples include postoperative pain, trauma, acute myocardial infarction, and acute appendicitis. **Chronic (persistent) pain** lasts longer than expected healing time (typically 3–6 months or longer) and may be unrelated to current tissue damage. Chronic pain lacks the outward sympathetic signs of acute pain because the body adapts (thus absence of tachycardia does not mean absence of pain). Instead, chronic pain is often accompanied by psychological effects: depression, anxiety, sleep disturbance, fatigue, social withdrawal, and functional limitation. Examples include arthritis, fibromyalgia, neuropathic pain, and cancer-related pain. The distinction is critical because management approaches differ: acute pain often involves analgesics and rest, while chronic pain requires multimodal, interdisciplinary approaches focusing on functional goals and quality of life.

**Nociceptive pain** results from activation of nociceptors by actual tissue damage and is divided into two types: **Somatic pain** originates from the skin, muscles, bones, and connective tissues (the soma). It is well-localized, described as aching, throbbing, sharp, or gnawing, and responsive to analgesics and NSAIDs. Examples include surgical wounds, fractures, burns, and muscle strains. **Visceral pain** originates from internal organs (the viscera) such as the heart, lungs, GI tract, liver, and kidneys. It is often deep, cramping, poorly localized, and may be referred to distant sites (e.g., cardiac pain radiating to the left arm or jaw, appendiceal pain referred to the periumbilical area). Visceral pain is also responsive to analgesics but may require different doses or types. Understanding the source and character of pain guides assessment, helps localize pathology, and informs treatment selection.

**Neuropathic pain** results from damage, dysfunction, or disease of the nervous system itself (peripheral or central nerves) rather than from ongoing tissue injury. It is described distinctly as burning, shooting, electric, tingling, numbness, or 'pins and needles' sensations. Neuropathic pain often feels abnormal and may be out of proportion to visible injury. Common causes include diabetic peripheral neuropathy, chemotherapy-induced neuropathy, spinal cord injury, stroke, shingles (post-herpetic neuralgia), and phantom limb pain after amputation. Neuropathic pain is poorly responsive to standard opioids and NSAIDs alone; it requires **adjuvant medications** such as antidepressants (amitriptyline, duloxetine) and anticonvulsants (gabapentin, pregabalin). Understanding neuropathic pain is crucial because standard analgesic ladders may not work, and appropriate adjuvant therapy is necessary for relief.

PQRST is a systematic mnemonic framework for characterizing pain comprehensively: **P—Provocation/Palliation**: What made the pain start? What makes it better or worse (e.g., movement, rest, heat, medication, position)? **Q—Quality**: How does the patient describe the pain? (e.g., sharp, dull, burning, cramping, aching, throbbing, electric, pressure) **R—Region and Radiation**: Where is the pain located? Does it travel or radiate elsewhere? **S—Severity**: How intense is the pain? Rate using appropriate scale (0–10, FLACC, etc.). **T—Timing**: When did it start? How long does it last? Is it constant or intermittent? What is the pattern (worse at certain times)? The PQRST framework provides a complete pain picture, aids in diagnosis, guides treatment selection, and documents the patient's pain experience clearly—essential for interdisciplinary communication and continuity of care.

Because pain is subjective, quantifying intensity requires patient-appropriate rating tools: **Numeric Rating Scale (NRS 0–10)** is the gold standard for verbally communicating adults and older children who can count and understand the continuum. Zero = no pain; 10 = worst pain imaginable. Simple, quick, and reliable for tracking pain over time and evaluating intervention effectiveness. **Wong-Baker FACES Scale** uses six cartoon faces ranging from happy/smiling (no pain) to crying (severe pain); useful for children approximately 3 years and older, adults with cognitive or language barriers, and non-English speakers. The patient or observer points to the face that matches their pain. **FLACC Scale (Face, Legs, Activity, Cry, Consolability)** is an observational tool for infants, young children, and nonverbal or severely cognitively impaired adults who cannot self-report. Each of the five components is scored 0–2, yielding a total 0–10. Scores: 0 = no pain; 1–3 = mild pain; 4–6 = moderate pain; 7–10 = severe pain. Other observational tools include the Behavioral Pain Scale (BPS) for critically ill sedated patients. Always choose the most appropriate tool for the patient's age and ability, and **reassess pain after interventions** (30–60 minutes after oral analgesics, 15–30 minutes after IV, and per institutional protocols) to measure effectiveness.

The World Health Organization analgesic ladder is the gold standard for systematic, stepwise pain management, especially for chronic and cancer pain. It guides drug selection based on pain intensity and ensures optimal use of each drug class before escalating: **Step 1 (Mild Pain: 0–3 on 0–10 scale)**: Start with **non-opioid analgesics**—acetaminophen (paracetamol) and/or NSAIDs (ibuprofen, naproxen, ketorolac), with or without adjuvant drugs (antidepressants, anticonvulsants). **Step 2 (Mild-to-Moderate Pain: 4–6)**: Add **weak opioids** (codeine, tramadol, low-dose hydrocodone) combined with non-opioids and adjuvants; do not abandon Step 1 drugs. **Step 3 (Moderate-to-Severe Pain: 7–10)**: Add or switch to **strong opioids** (morphine, hydromorphone, fentanyl, oxycodone) combined with non-opioids and adjuvants. If pain intensifies, ascend one step; if pain decreases, descend. Give analgesics **around the clock** (scheduled, not PRN) for continuous pain to maintain steady blood levels; use short-acting 'breakthrough' doses for episodic increases. The ladder prevents both undertreatment and premature escalation and ensures multimodal approaches that reduce opioid requirements.

**Acetaminophen (paracetamol)** is an analgesic and antipyretic (fever-reducing) agent with minimal anti-inflammatory effect. It works centrally to block pain and fever perception, likely by inhibiting prostaglandins in the brain. **Dosing**: Typical adult dose is 500–1000 mg every 4–6 hours, not to exceed approximately **4 g per day** (or 3 g/day in older adults, those with liver disease, or those consuming alcohol). Lower doses are recommended in hepatic impairment. **Advantages**: Minimal GI upset (unlike NSAIDs), no bleeding risk, and safe in pregnancy (Category A/B depending on trimester). **Critical Safety Concern—Hepatotoxicity**: The major danger of acetaminophen is **dose-dependent hepatotoxicity (liver damage)** when total daily intake exceeds recommended limits or in susceptible individuals (chronic liver disease, alcoholism). Acute overdose can cause acute liver failure; chronic overdose causes cirrhosis. **Antidote**: **N-acetylcysteine (acetylcysteine)** is the specific antidote for acetaminophen overdose and must be given promptly. **Nursing Considerations**: Educate patients that many over-the-counter cold, flu, and allergy products contain hidden acetaminophen—teach them to check labels to avoid accidental overdose. Monitor liver function if used long-term or in at-risk patients. Do not combine with other acetaminophen-containing products.

**NSAIDs** (e.g., ibuprofen, naproxen, meloxicam, ketorolac) reduce pain, fever, and inflammation by inhibiting prostaglandin synthesis via cyclooxygenase (COX) inhibition. **Mechanism**: Prostaglandins promote inflammation, pain, and fever; NSAIDs block their production, addressing all three. **Dosing Examples**: Ibuprofen 400–600 mg every 4–6 hours (max ~3200 mg/day); Ketorolac (Toradol) 15–30 mg IV/IM every 4–6 hours for acute pain (not more than 5 days). **Advantages**: No respiratory depression, no addiction potential, strong anti-inflammatory effect, oral and IV options, and no opioid tolerance development. **Critical Adverse Effects**: (1) **GI bleeding and ulceration**—NSAIDs inhibit protective gastric prostaglandins, increasing risk of gastritis, ulcers, and GI hemorrhage (presenting as black, tarry stools, coffee-ground vomiting, or hematemesis). (2) **Renal impairment**—NSAIDs reduce renal blood flow and glomerular filtration, especially in dehydrated patients or those with pre-existing renal disease, causing acute kidney injury. (3) **Increased bleeding**—NSAIDs inhibit platelet aggregation, increasing bleeding risk in patients on anticoagulants or with bleeding disorders. (4) **Cardiovascular effects**—long-term NSAIDs may increase risk of MI and stroke. **Nursing Considerations**: Always give NSAIDs **with food or milk** to reduce GI upset. Monitor for signs of GI bleeding (dark stools, abdominal pain, vomiting). Use cautiously in older adults, those with peptic ulcer disease, renal impairment, heart disease, or on anticoagulants (warfarin, heparin). Ketorolac, the most potent NSAID, is reserved for short-term acute pain (max 5 days) due to high GI and renal risk; do not use long-term. Provide patient education about safe dosing and avoiding duplicate therapy (e.g., not combining ibuprofen with naproxen).

**Opioids** are potent analgesics that bind to opioid receptors (mu, kappa, delta) in the brain, spinal cord, and GI tract, reducing the perception and emotional response to pain. They are classified as: **Strong opioids** (morphine, hydromorphone, fentanyl, oxycodone, methadone) are used for moderate-to-severe pain and are the Step 3 agents of the WHO ladder. **Morphine** is the reference opioid: a typical IV dose is 2–10 mg every 2–4 hours; an oral dose is 10–30 mg every 3–4 hours, titrated to effect. **Fentanyl** is 50–100 times more potent than morphine and is used IV, transdermal (patch), intranasal, or sublingual. **Hydromorphone** is 5–7 times more potent than morphine. **Weak opioids** (codeine, tramadol, hydrocodone) are used for mild-to-moderate pain (Step 2) or as adjuncts. **Mechanism**: Opioids bind to opioid receptors and activate inhibitory pathways in the CNS, reducing transmission and perception of pain while also affecting emotion and the affective component of pain, which is why they are especially useful for severe and cancer pain. **Clinical Uses**: Moderate-to-severe acute pain (postoperative, trauma), chronic cancer pain, dyspnea in palliative care, and myocardial infarction-related pain. **Onset and Duration**: IV opioids have rapid onset (5–15 minutes) and shorter duration (2–4 hours); oral opioids have slower onset (30–60 minutes) and longer duration (3–6 hours); transdermal patches provide continuous delivery over 48–72 hours.

Opioids carry significant risks requiring vigilant nursing management. **The five most important adverse effects are**: (1) **Respiratory Depression**—the most dangerous and dose-limiting adverse effect. Opioids depress the respiratory center in the medulla, reducing respiratory rate, depth, and effort. Severe respiratory depression (RR < 8–12 breaths/min, shallow breathing, SpO2 < 90%) can lead to hypoxemia, hypercarbia, and death if untreated. Respiratory depression develops gradually and is preceded by increasing sedation, so sedation is a warning sign. **Critical Nursing Rule: Always assess respiratory rate BEFORE administering an opioid. Hold the dose and notify the provider immediately if RR is below 12 breaths per minute.** (Institutional policies vary; 10–12 is common.) Monitor RR, SpO2, and level of consciousness closely for the first 1–2 hours after IV opioids and after dose increases. (2) **Constipation**—extremely common and does NOT improve with tolerance (unlike nausea or drowsiness). Opioids slow GI motility and increase water reabsorption, causing hard, infrequent stools. Untreated constipation leads to impaction, obstruction, and severe discomfort. **Prevent proactively**: Increase fluids (if not contraindicated), increase fiber, encourage ambulation, and start a bowel regimen (stool softener + stimulant laxative, e.g., docusate + senna) when opioid therapy begins. Monitor bowel movements daily. (3) **Sedation and Drowsiness**—common, especially with initial doses or escalation. Assess level of consciousness; mild drowsiness usually improves with tolerance, but increasing sedation is a warning of impending respiratory depression. (4) **Nausea and Vomiting**—occur in 20–30% of patients, often on initial doses or with rapid escalation; may improve with tolerance or antiemetics. (5) **Urinary Retention**—opioids relax smooth muscle, reducing bladder contractility; monitor urine output, especially postoperatively. **Other Adverse Effects**: Miosis (pinpoint pupils—a classic sign of opioid effect), hypotension (especially with IV boluses), pruritus (itching), myosis, and histamine release (flush, flushing, rarely anaphylaxis with IV push). **Tolerance, Dependence, and Addiction** (distinct concepts): **Tolerance** = needing increasingly higher doses to achieve the same effect (purely physiologic, expected with chronic use, not the same as addiction). **Physical Dependence** = the body adapts; abrupt cessation causes withdrawal symptoms (anxiety, pain, sweating, diarrhea, rapid heart rate)—expected and not addiction. **Addiction** = compulsive drug-seeking behavior despite harm, characterized by loss of control and continued use despite negative consequences—a psychological condition requiring treatment. **Nursing Responsibility**: Provide adequate pain relief without fear of causing addiction (a common misconception leading to undertreatment); monitor for signs of addiction (request patterns, escalating doses without medical cause, drug-seeking behavior); and use protocols for safe opioid prescribing and monitoring, especially for patients with substance use disorder history (do not deny pain relief, but have clear agreements and monitoring).

**Naloxone (Narcan)** is an **opioid antagonist** that reverses the effects of opioids by competitively binding to opioid receptors with high affinity but producing no analgesic or respiratory depressant effects—it is the specific antidote for opioid overdose. **Indications**: Opioid overdose manifesting as respiratory depression (RR < 8, SpO2 < 90%), unresponsiveness, or pinpoint pupils unresponsive to other measures. **Dosing**: Initial IV dose is typically 0.04–0.4 mg (varies by protocol); can repeat every 2–3 minutes if needed, up to a total dose per protocol (often 2–10 mg total). IM or intranasal forms exist for prehospital or emergency use. **Onset and Duration**: **Rapid onset (1–5 minutes IV)** but **short duration (30–90 minutes depending on formulation)**. This is a **critical limitation**: naloxone may wear off before the opioid does (especially long-acting opioids like morphine extended-release or methadone), allowing the opioid's effects to re-emerge and respiratory depression to recur. Therefore, **patients given naloxone must be monitored closely for at least 2–4 hours after the last dose**; may need a continuous naloxone infusion or repeated doses. **Adverse Effects of Naloxone**: Because naloxone is an antagonist, it **abruptly blocks all opioid effects**, precipitating acute opioid withdrawal: agitation, anxiety, body aches, sweating, tachycardia, hypertension, and sudden return of severe pain (in patients who were receiving opioids for chronic pain). While uncomfortable, acute withdrawal is not life-threatening, and the reversal of respiratory depression justifies it. **Nursing Responsibilities**: (1) Keep naloxone readily available in settings where opioids are given (operating rooms, post-anesthesia care, ICUs, palliative care). (2) Recognize overdose: respiratory depression, unresponsiveness, pinpoint pupils, low SpO2. (3) Administer naloxone per protocol immediately and notify the provider. (4) Monitor respiratory rate, consciousness, blood pressure, and oxygen saturation continuously for at least 2–4 hours. (5) Warn the patient and family that naloxone is not a substitute for medical care and overdose requires emergency evaluation. (6) Do not label naloxone reversal as an overdose = addiction; clarify that some patients overdose unintentionally (medication errors, tolerance loss after abstinence, unknown opioid potency in illicit drugs).

**Patient-Controlled Analgesia (PCA)** is a system in which the patient self-administers preset IV doses of opioid analgesic by pressing a button, providing greater pain control, reduced anxiety from waiting for nurse-administered doses, improved satisfaction, and often lower total opioid consumption because patients titrate to their individual needs. **How PCA Works**: An infusion pump is programmed with: **Demand dose** (e.g., 1 mg morphine), **lockout interval** (e.g., 6 minutes—the minimum time between doses), **basal rate** (optional continuous infusion, e.g., 0.5 mg/hour), and **4-hour limit** (e.g., max 30 mg in 4 hours). When the patient presses the button, the pump delivers the demand dose if the lockout interval has elapsed; if the button is pressed before lockout expires, the pump does not deliver a dose (safety feature preventing overdose). **Advantages**: Better pain control (patient response is faster than nurse call light), sense of control and empowerment, reduced anxiety, lower opioid consumption. **Critical Safety Rule—'PCA by Proxy' is Forbidden**: **Only the patient should press the button.** Family members, visitors, or nursing staff must NEVER press the button for the patient ('PCA by proxy'). This is because the patient develops sedation as opioids accumulate and may fall asleep, at which point they cannot self-limit further doses; a family member, however, may continue pressing the button, leading to overdose, respiratory depression, and death. PCA by proxy is a leading cause of preventable opioid-related deaths in hospitals. **Nursing Responsibilities**: (1) **Teach the patient clearly**: 'Press the button when your pain starts. Only YOU press the button—not family, not visitors, not staff. If you fall asleep, you won't press it, which is safe.' (2) **Assess and document**: respiratory rate, oxygen saturation, level of consciousness (check before each dose ideally, or frequently). (3) **Verify the order**: A second nurse must verify the drug, concentration, dose, lockout, and 4-hour limit before initiation and during shifts. (4) **Monitor output**: Document number of doses delivered and attempted (device displays both; if attempted >> delivered, patient may have uncontrolled pain and needs provider evaluation). (5) **Ensure safety equipment**: A **naloxone kit, oxygen, and resuscitation equipment** must be immediately available. (6) **Assess pain relief**: Ask the patient if pain is controlled; adjust settings per provider order if needed. (7) **Educate family**: Reassure them that the lockout interval and basal rate ensure safety; explain PCA by proxy danger clearly.

Non-pharmacologic (non-drug) pain management strategies complement analgesics and activate the body's intrinsic pain-relief mechanisms, particularly through the gate control theory. By engaging large-diameter sensory fibers or activating descending inhibitory pathways, these measures reduce pain transmission and opioid requirements. **Gate Control Strategies (Closing the Gate)**: (1) **Cutaneous stimulation**—tactile stimuli 'close the gate' by activating large-diameter touch/pressure fibers: **Therapeutic Heat**—moist heat (warm compresses, heating pads) increases blood flow, relaxes muscle, and is soothing; apply for 15–20 minutes, not directly to skin (risk of burn; use barrier). Contraindicated if edema is present (worsens swelling). (2) **Cold (Cryotherapy)**—ice, cold packs reduce pain from acute inflammation and trauma by numbing, reducing edema, and slowing nerve conduction; apply for 15–20 minutes with barrier. Less well-tolerated than heat but useful for acute injuries and post-op swelling. (3) **Massage and Pressure**—gentle massage, stroking, or sustained pressure over painful areas closes the gate and promotes relaxation; enhances blood flow and reduces muscle tension. (4) **Transcutaneous Electrical Nerve Stimulation (TENS)**—a battery-operated device applies mild electrical current via electrodes on the skin, stimulating large sensory fibers to close the gate; effective for chronic musculoskeletal pain, postoperative pain, and neuropathic pain. **Cognitive-Behavioral Strategies (Modulating the Gate)**: (5) **Relaxation and Deep Breathing**—slow, diaphragmatic breathing activates the parasympathetic nervous system, reduces anxiety, and lowers muscle tension; teach techniques like 4-7-8 breathing (inhale 4 counts, hold 7, exhale 8). (6) **Guided Imagery**—patient mentally visualizes a peaceful, safe place (beach, forest), engaging the imagination to redirect attention away from pain and activate endogenous opioids. (7) **Distraction**—engaging activities (music, conversation, TV, games, puzzles) shift attention from pain to external stimuli; highly effective, especially for acute pain. (8) **Music Therapy**—listening to preferred music reduces pain perception, anxiety, and need for analgesics; offer choices and play for 30–45 minutes. (9) **Biofeedback**—teaches patients to monitor and control physiologic responses (heart rate, muscle tension) via visual feedback, promoting relaxation and pain reduction. **Physical Strategies**: (10) **Positioning and Immobilization**—proper body alignment and support reduce pain from surgery, trauma, or inflammation; pillows for support, splints for injured limbs. (11) **Rest and Sleep**—fatigue worsens pain perception; promote quality sleep with comfortable environment, noise reduction, pain management before sleep. (12) **Acupuncture and Acupressure**—traditional Chinese medicine techniques; acupuncture (fine needles in specific points) and acupressure (finger pressure on points) have growing evidence for chronic pain relief and are now incorporated in many pain centers. **Special Considerations for Chronic Pain**: Non-pharmacologic strategies are **especially valuable** for chronic pain where long-term analgesic use is limited and functional goals are paramount. They reduce opioid consumption, improve coping, and address the psychological and social dimensions of chronic pain. **Documentation and Evaluation**: Document all non-pharmacologic measures used and evaluate their effectiveness using pain scales; if effective, continue and encourage patient self-use.

Analgesics are administered via multiple routes, each with advantages, onset times, and appropriate clinical contexts. **Oral (PO)**—the preferred route when tolerated: advantages include convenience, lower cost, no need for IV access, and suitable for chronic pain; disadvantages are slower onset (30–60 minutes for tablets, 15–30 for liquids), variable absorption affected by GI function, and inability to use in NPO patients or those unable to swallow. **Intravenous (IV)**—fastest onset (5–15 minutes), most reliable, ideal for severe acute pain (post-op, trauma, MI); disadvantages are need for IV access, higher cost, rapid onset requires close monitoring for adverse effects, and shorter duration requiring more frequent dosing. Can be given as bolus (rapid effect but higher overdose risk if unlabeled or confused) or slow IV infusion (safer, more stable). **Intramuscular (IM)**—once common, now discouraged for pain management because absorption is unpredictable, painful, and provides no advantage over oral or IV; still used occasionally for acute emergencies when IV not available. **Subcutaneous—**useful in palliative care and when IV access is difficult; slower than IV but faster than oral. **Transdermal (Patches)**—fentanyl patches deliver opioid continuously through the skin over 48–72 hours; used ONLY for stable chronic pain in opioid-tolerant patients, not for acute or opioid-naive patients (risk of fatal overdose). **Rectal (PR)**—suppositories or liquids used when oral/IV not feasible (unconscious, severe nausea, perioperative); useful in palliative care. **Intranasal**—rapid absorption for acute breakthrough pain, especially fentanyl sprays/lozenges. **Epidural and Intrathecal—**pain medication injected into the space around the spinal cord (epidural) or into CSF (intrathecal); used in post-op pain, labor pain, and chronic cancer pain; requires specialized equipment and monitoring; provides excellent pain relief with lower systemic doses. **Sublingual/Buccal—**fentanyl lozenges or tablets absorbed through mucous membranes; rapid onset, useful for breakthrough pain. **Equianalgesic Dosing**: When switching routes or drugs (e.g., from IV morphine to oral), equianalgesic dosing charts are essential to provide equivalent pain relief without under- or over-dosing. Example: 10 mg IV morphine ≈ 30 mg oral morphine (morphine has lower oral bioavailability). **Clinical Selection**: For acute severe pain (post-op, trauma), IV is fastest. For chronic pain, oral long-acting formulations are preferred for convenience and steady levels. For patients with swallowing difficulties or nausea, transdermal or rectal may be chosen. For breakthrough pain in cancer patients, rapid-onset formulations (intranasal fentanyl, immediate-release oral opioids) are used.

Chronic pain (persisting beyond 3–6 months, often unrelated to ongoing tissue damage) requires a **multimodal, interdisciplinary approach** far different from acute pain management. **Why Multimodal?**: Chronic pain involves complex physiology, psychology, and social factors; no single intervention addresses all dimensions. Combining pharmacologic, physical, psychological, and social interventions provides greater relief and functional improvement than any single approach and reduces opioid requirements, lowering risks. **Components of a Comprehensive Chronic Pain Plan**: (1) **Pharmacologic Management**: Use the WHO ladder; long-acting opioids (e.g., extended-release morphine, transdermal fentanyl) for baseline control, with short-acting formulations for breakthrough pain; add non-opioid analgesics and **adjuvants**: antidepressants (amitriptyline, duloxetine) and anticonvulsants (gabapentin, pregabalin) especially for neuropathic pain. (2) **Physical Interventions**: Physical therapy to improve strength, flexibility, and function; occupational therapy to adapt activities of daily living; heat, cold, massage, TENS. (3) **Psychological Support**: Cognitive-behavioral therapy (CBT) to address pain catastrophizing, develop coping strategies, and improve mood; mindfulness and acceptance-based approaches; treatment of comorbid depression and anxiety. (4) **Functional Goals**: Rather than pursuing pain elimination (often unrealistic in chronic pain), set **functional goals**: improved sleep, return to work, increased social activity, better quality of life. Reassess progress toward goals, not just pain scores. (5) **Social and Occupational Support**: Pain rehabilitation programs, support groups, vocational counseling, family education. (6) **Interdisciplinary Team**: Pain physician, nurse, physical therapist, psychologist, social worker, and other specialists meet regularly to coordinate care and adjust the plan based on progress. **Opioid Considerations in Chronic Pain**: Long-term opioid therapy for chronic non-cancer pain is increasingly restricted due to overdose risks and limited efficacy beyond 6–12 months in most conditions, but **opioids remain appropriate for well-selected, monitored patients** (cancer pain, advanced disease pain). Use clear **opioid agreements** with chronic pain patients (specify quantity, refill frequency, prohibited behaviors like selling or sharing); monitor regularly; screen for substance use disorder; do not deny opioids to patients with a history of substance use if they meet criteria and have support (stabilize them on buprenorphine or methadone if appropriate). Distinguish **tolerance** (needing higher doses—physiologic and expected), **physical dependence** (withdrawal on cessation—expected and not addiction), and **addiction** (compulsive use despite harm—psychological, rare in patients without prior addiction vulnerability). **Documentation and Reassessment**: Document the multimodal plan, patient's functional status, pain levels, opioid doses, and side effects. Reassess at regular intervals (monthly initially, then as appropriate) and adjust interventions based on progress toward functional goals, not pursuit of zero pain.

Optimal pain management requires adaptation to individual patient characteristics. **Older Adults (Aged 65+)**: Older adults experience pain as frequently as younger adults but are undertreated due to myths that pain is 'normal' aging and concerns about drug interactions. Physiologic changes require dose adjustment: (1) **Increased Sensitivity to Opioids**—reduced metabolism and clearance lead to higher blood levels; delayed sedation, respiratory depression from lower doses; start with 50% of standard adult dose and titrate slowly. (2) **Reduced Clearance of Other Drugs**—NSAIDs accumulate in kidneys (already declining with age); increased GI bleeding risk; use cautiously with renal monitoring. (3) **Polypharmacy and Drug Interactions**—older adults often take multiple medications; evaluate for interactions. (4) **Cognitive Impairment**—may affect pain assessment and report; use observational tools and family input; simplified instructions. (5) **Fall Risk**—opioid-induced sedation increases fall and fracture risk; assess fall risk and implement precautions. **Approach**: Start low (lower doses), go slow (gradual titration), and reassess often (frequently check effectiveness and adverse effects). Use non-pharmacologic measures prominently. **Opioid-Naive Patients** (never or rarely used opioids): More sensitive to side effects, especially respiratory depression; require closer monitoring. Start lowest available doses and escalate slowly. Consider non-opioid and adjuvant therapies before opioids. Assess respiratory status carefully pre-dose and post-dose. **Children**: Pain assessment depends on age: infants/toddlers (< 3 years) use FLACC or parent observation; preschoolers (3–5 years) use Wong-Baker FACES or simple pain scales (1–5); school-age (5+) and adolescents often use 0–10 numeric scale. **Opioid Dosing**: Always dose by weight (e.g., 0.1 mg/kg morphine); use pediatric references. Children have higher analgesic needs per weight than adults. Prevent constipation aggressively (children are prone to severe impaction). Provide emotional support and non-pharmacologic measures (distraction, play therapy, parent presence). Avoid IM injections if possible (traumatic for children). **Patients with History of Substance Use Disorder**: High-risk for opioid misuse and overdose, but **deserve adequate pain relief**; do not deny opioids based on history alone. Use **controlled-substance agreements** specifying quantity, refill frequency, random urine screens; monitor for behaviors suggestive of misuse (seeking early refills, losing prescriptions, obtaining from multiple providers). Consider medication-assisted treatment (MAT) with buprenorphine or methadone if appropriate; buprenorphine has lower overdose risk and can be used in primary care. Coordinate with addiction specialists. Communicate clearly: 'We will treat your pain, and we will monitor carefully to keep you safe.' **Documentation**: Always document patient-specific considerations (age, renal function, cognitive status, substance use history, medication list) and how they informed pain management decisions.